Otezla is the first and only oral therapy approved across all severities of adult plaque psoriasis SEE THE DATA
*66.3% of commercially insured patients have preferred access to Otezla with no DMARD step or biologic step for PsA and 63.2% of commercially insured patients have preferred access to Otezla with no DMARD step or biologic step for moderate to severe plaque psoriasis.
Otezla is now covered by ~99% of commercial insurance plans nationally 1,†
Commercially insured patients can get Otezla for $0 per month with the Otezla Co-Pay Card ‡
The Bridge Program offers your commercially insured patients Otezla for free while awaiting coverage approval §
†Local coverage may vary. ‡The Otezla Co-Pay Card is for eligible commercially insured patients. Terms, conditions, and program maximums apply. Other restrictions may apply. Please see full Terms and Conditions. This program is not open to patients receiving prescription reimbursement under any federal, state, or government-funded healthcare program. Not valid where prohibited by law. Patients who are not eligible can call 1-844-4OTEZLA to discuss further financial support opportunities. §If the patient’s health plan requires a prior authorization or if patient experiences a delay in obtaining approval for Otezla, patients can qualify for the Bridge to Commercial Coverage Offer and receive Otezla free for up to 12 months while pursuing approval from their health plan. No purchase necessary. Please see full Terms and Conditions.
The Otezla Nurse Partner ** program works closely with your new Otezla patients to provide tailored support, including how to get started on Otezla, maintaining a treatment routine, and guiding them to resources based on their individual goals.
Enrollment is simple for your Otezla patients. Encourage them to sign up for Otezla SupportPlus™ to access the Otezla Nurse Partner program today!
**Otezla Nurse Partners are nurses by training, but they are not part of a patient’s treatment team or an extension of their doctor’s office. Patients will be referred to their doctor’s office for clinical advice.
DMARD, disease-modifying antirheumatic drug; PA, prior authorization; PsA, psoriatic arthritis.
Warnings and Precautions
Use in Specific Populations
Please click here for the full Prescribing Information.
Otezla® (apremilast) is indicated for the treatment of adult patients with plaque psoriasis who are candidates for phototherapy or systemic therapy.
Otezla is indicated for the treatment of adult patients with active psoriatic arthritis.
Otezla is indicated for the treatment of adult patients with oral ulcers associated with Behçet’s Disease.
Reference: 1. Data on file, Amgen Inc.